Cogent Biosciences COGT
Ownership & positioning
Who holds it, who is betting against it, and where the big money is moving
Short-sale volume as % of daily volume
Large-order net flow, last 20 sessions
Net of large-order buying minus selling, in USD. Over this window: −$15.12M (8 inflow days, 12 outflow days).
Net flow by order size, last 20 sessions
Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.
The five largest holders on file together own 38.7% of shares outstanding.
Largest holders
By investor type
Reported short interest has fallen from 10.61% to 10.04% of float over the last 6 biweekly reports (14 Aug 2026 to 30 Oct 2026).
Recent institutional activity
| Holder | Type | Period | Share change | New stake |
|---|---|---|---|---|
| Franklin Resources | Mutual Fund | 2026/Q3 | +1,775,758 | 1.1% |
| FMR | Mutual Fund | 2026/Q3 | +1,170,841 | 15.4% |
| Loomis, Sayles & Company L.P. | Mutual Fund | 2026/Q3 | +1,115,760 | 0.6% |
| State Street Global Advisors | Mutual Fund | 2026/Q3 | +805,230 | 4.5% |
| UBS Asset Management | Mutual Fund | 2026/Q3 | +555,849 | 1.1% |
| Pictet Asset Management Limited | Mutual Fund | 2026/Q3 | +449,261 | 1.6% |
| Polar Capital Holdings Plc | Mutual Fund | 2026/Q3 | +3,232,905 | 1.9% |
| FMR | Mutual Fund | 2026/Q3 | +2,558,484 | 14.8% |
| T. Rowe Price Group, Inc. | Mutual Fund | 2026/Q3 | +1,439,912 | 2.7% |
| OrbiMed Advisors LLC | VC/PE Fund | 2026/Q3 | +1,359,200 | 1.0% |
| BlackRock | Mutual Fund | 2026/Q3 | +1,307,632 | 10.0% |
| State Street Global Advisors | Mutual Fund | 2026/Q3 | +1,301,376 | 4.0% |
| Assenagon Asset Management S.A. | Mutual Fund | 2026/Q3 | +1,146,106 | 0.8% |
| Woodline Partners LP | Hedge Fund | 2026/Q3 | +1,093,605 | 1.5% |
| Deep Track Capital, LP | VC/PE Fund | 2026/Q3 | +1,000,000 | 1.1% |
Institutional buy/sell activity by reporting period, largest moves first.
Insider transactions
| Date | Insider | Title | Transaction | Shares | Price | Held after |
|---|---|---|---|---|---|---|
| 30 Sep 2026 | Karen Jean Ferrante | Independent Director | Other Derivative Acquisition | +759 | $31.59 | 759 |
| 26 Aug 2026 | Arlene Morris | Independent Director | Derivative Exercise and Sale | -45,510 | $37.54 | – |
| 30 Jun 2026 | Karen Jean Ferrante | Independent Director | Other Derivative Acquisition | +627 | $38.48 | 627 |
| 8 Jun 2026 | Arlene Morris | Independent Director | Other Derivative Acquisition | +17,901 | $31.98 | 17,901 |
| 8 Jun 2026 | Matthew Ros | Independent Director | Other Derivative Acquisition | +17,901 | $31.98 | 17,901 |
| 8 Jun 2026 | Todd Shegog | Independent Director | Other Derivative Acquisition | +17,901 | $31.98 | 17,901 |
| 8 Jun 2026 | Karen Jean Ferrante | Independent Director | Other Derivative Acquisition | +17,901 | $31.98 | 17,901 |
| 8 Jun 2026 | Christopher Cain | Independent Director | Other Derivative Acquisition | +17,901 | $31.98 | 17,901 |
| 8 Jun 2026 | Peter Harwin | Independent Chairperson | Other Derivative Acquisition | +17,901 | $31.98 | 17,901 |
| 18 May 2026 | Andrew Robbins | Chief Executive Officer | Other Acquisition | +160,000 | – | 472,503 |
| 18 May 2026 | Andrew Robbins | Chief Executive Officer | Other Disposition | -160,000 | – | 472,503 |
| 31 Mar 2026 | Karen Jean Ferrante | Independent Director | Other Derivative Acquisition | +686 | $35.24 | 686 |
| 30 Mar 2026 | Fairmount Funds Management LLC | Derivative Exercise and Sale | -7,000,000 | $34.66 | 5,503,418 | |
| 21 Jan 2026 | Fairmount Funds Management LLC | Private Disposition | -3,500,000 | $36.40 | 5,503,418 | |
| 31 Dec 2025 | Karen Jean Ferrante | Independent Director | Other Derivative Acquisition | +643 | $34.74 | 643 |
| 25 Dec 2025 | John Green | Chief Financial Officer | Open Market Disposition | -77,000 | $38.68 | 81,834 |
| 25 Dec 2025 | Evan Kearns | Chief Legal Officer | Open Market Disposition | -65,000 | $38.70 | 69,398 |
| 25 Dec 2025 | Jessica Sachs | Chief Medical Officer | Open Market Disposition | -82,642 | $38.70 | 83,938 |
| 25 Dec 2025 | John Robinson | Chief Scientific Officer | Open Market Disposition | -90,000 | $38.74 | 90,002 |
| 16 Dec 2025 | Andrew Robbins | Chief Executive Officer | Sale to Issuer | -367,497 | $39.45 | 472,503 |
From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.
Short interest, by report
| Report date | Shares short | % of float | Days to cover |
|---|---|---|---|
| 30 Oct 2026 | 17,416,118 | 10.0% | 8.7 |
| 15 Oct 2026 | 19,661,566 | 11.3% | 8.9 |
| 30 Sep 2026 | 19,462,718 | 11.2% | 8.1 |
| 15 Sep 2026 | 18,126,492 | 10.4% | 11.8 |
| 31 Aug 2026 | 18,747,531 | 10.8% | 12.1 |
| 14 Aug 2026 | 18,411,111 | 10.6% | 9.0 |
No comments yet — be the first to weigh in on COGT.
Sign in to join the discussion.